A new review published in Current Pharmaceutical Analysis provides an in-depth look at the latest analytical techniques used for impurity profiling and forced degradation studies of Angiotensin (AT1) ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

The results showed that people taking ARBs had a 63% higher risk of suicide compared to those taking ACE inhibitors. One ...

GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a ...

Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...

G protein-coupled receptors (GPCRs) make up the largest receptor family in humans, which also constitute principal molecular targets for about 36% of approved drugs. Recent studies show that GPCRs can ...

Blockade of the A2A adenosine receptor (A2AAR) by small-molecule antagonists holds promise for enhancing the efficacy of immune checkpoint inhibitors such as PD-L1 antibodies. However, many A2AAR ...